Stock Track | Ultragenyx Pharmaceutical Soars 5.32% Intraday on Positive Analyst Ratings

Stock Track
May 06

Ultragenyx Pharmaceutical's stock surged 5.32% during intraday trading on Wednesday, following a series of positive analyst actions from major financial institutions.

The price movement appears to be driven by favorable analyst coverage, with Wells Fargo maintaining a Buy rating on the stock and raising its price target from $45 to $47. Barclays also maintained a Buy rating with a $43 price target, contributing to positive sentiment around the healthcare company.

Analyst coverage of Ultragenyx Pharmaceutical has been active, with multiple firms weighing in on the stock. While Wedbush maintained a Neutral rating, the overall analyst sentiment appears positive, with the company having an average Buy rating and mean price target of $53.30 according to FactSet data.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10